Wen Dong1, Xiong Chen1, Ming Huang1, Xu Chen1, Ming Gao2, Dehua Ou1, Kaiwen Li1, Chenyang Wang1, Shaoxu Wu1, Hao Liu1, Weibin Xie1, Wenlian Xie1, Steven C Campbell3, Tianxin Lin1, Jian Huang1. 1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. 2. Department of Radiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. 3. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, United States.
Abstract
OBJECTIVES: Tumor enucleation (TE) optimizes parenchymal preservation with promising short-term oncologic outcomes compared with standard partial nephrectomy (SPN). However, researches/literatures about long-term oncologic outcomes for TE after minimally invasive surgery are scarce. We aim to analyze long-term oncologic outcomes after laparoscopic and robotic tumor enucleation for renal cell carcinoma (RCC). PATIENTS AND METHODS: We retrospectively analyzed 146 patients who underwent TE with either laparoscopic or robotic approach for localized RCC in our center. Local recurrence, cancer specific survival (CSS), recurrence free survival (RFS), and overall survival (OS) were the main outcomes. Survival curves were generated using a Kaplan-Meier method. Perioperative outcomes and pathological outcomes were also analyzed. RESULTS: Overall, 98 male and 48 female patients were eligible for the study. The median tumor size was 3.4 cm with a median R.E.N.A.L. score of seven. Warm ischemia was used in 143 patients with a median ischemia time of 20 min and three patients had zero ischemia. Five patients (3.4%) had major complications (> Clavien IIIa) and only two were related to urinary system. The median global glomerular filtration rate (GFR) preserved after surgery was 93%. Pseudocapsule invasion was reported in 50 tumors (34%) and positive surgical margins were found in 3/146 (2.1%) tumors. At a median follow-up of 66 months, local recurrence happened in two patients (1.4%), and systemic recurrence happened in six patients (4.2%). The 5-year CSS, RFS, OS were 95.7, 89.6, and 91.9%, and the 10-year CSS, RFS, OS were 93.8, 89.6, and 90.0%, respectively. CONCLUSION: This study indicates that tumor enucleation with laparoscopic or robotic approach in experienced hands for the treatment of RCC appears oncologically safe with a median follow-up of more than 5 years. Prospective studies with more patients and longer follow-up will be required to further evaluate oncologic safety after TE.
OBJECTIVES: Tumor enucleation (TE) optimizes parenchymal preservation with promising short-term oncologic outcomes compared with standard partial nephrectomy (SPN). However, researches/literatures about long-term oncologic outcomes for TE after minimally invasive surgery are scarce. We aim to analyze long-term oncologic outcomes after laparoscopic and robotic tumor enucleation for renal cell carcinoma (RCC). PATIENTS AND METHODS: We retrospectively analyzed 146 patients who underwent TE with either laparoscopic or robotic approach for localized RCC in our center. Local recurrence, cancer specific survival (CSS), recurrence free survival (RFS), and overall survival (OS) were the main outcomes. Survival curves were generated using a Kaplan-Meier method. Perioperative outcomes and pathological outcomes were also analyzed. RESULTS: Overall, 98 male and 48 female patients were eligible for the study. The median tumor size was 3.4 cm with a median R.E.N.A.L. score of seven. Warm ischemia was used in 143 patients with a median ischemia time of 20 min and three patients had zero ischemia. Five patients (3.4%) had major complications (> Clavien IIIa) and only two were related to urinary system. The median global glomerular filtration rate (GFR) preserved after surgery was 93%. Pseudocapsule invasion was reported in 50 tumors (34%) and positive surgical margins were found in 3/146 (2.1%) tumors. At a median follow-up of 66 months, local recurrence happened in two patients (1.4%), and systemic recurrence happened in six patients (4.2%). The 5-year CSS, RFS, OS were 95.7, 89.6, and 91.9%, and the 10-year CSS, RFS, OS were 93.8, 89.6, and 90.0%, respectively. CONCLUSION: This study indicates that tumor enucleation with laparoscopic or robotic approach in experienced hands for the treatment of RCC appears oncologically safe with a median follow-up of more than 5 years. Prospective studies with more patients and longer follow-up will be required to further evaluate oncologic safety after TE.
Authors: Hendrik Van Poppel; Luigi Da Pozzo; Walter Albrecht; Vsevolod Matveev; Aldo Bono; Andrzej Borkowski; Marc Colombel; Laurence Klotz; Eila Skinner; Thomas Keane; Sandrine Marreaud; Sandra Collette; Richard Sylvester Journal: Eur Urol Date: 2010-12-22 Impact factor: 20.096
Authors: Börje Ljungberg; Laurance Albiges; Yasmin Abu-Ghanem; Karim Bensalah; Saeed Dabestani; Sergio Fernández-Pello; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Teele Kuusk; Thomas B Lam; Lorenzo Marconi; Axel S Merseburger; Thomas Powles; Michael Staehler; Rana Tahbaz; Alessandro Volpe; Axel Bex Journal: Eur Urol Date: 2019-02-23 Impact factor: 20.096
Authors: Robert H Blackwell; Belinda Li; Zachary Kozel; Zhiling Zhang; Juping Zhao; Wen Dong; Sarah E Capodice; Gregory Barton; Arpeet Shah; Jessica J Wetterlin; Marcus L Quek; Steven C Campbell; Gopal N Gupta Journal: Urology Date: 2016-09-07 Impact factor: 2.649
Authors: Fabrizio Di Maida; Riccardo Campi; Brian R Lane; Ottavio De Cobelli; Francesco Sanguedolce; Georgios Hatzichristodoulou; Alessandro Antonelli; Antonio Andrea Grosso; Sabrina Noyes; Oscar Rodriguez-Faba; Frank X Keeley; Johan Langenhuijsen; Gennaro Musi; Tobias Klatte; Marco Roscigno; Bulent Akdogan; Maria Furlan; Claudio Simeone; Nihat Karakoyunlu; Martin Marszalek; Umberto Capitanio; Alessandro Volpe; Sabine Brookman-May; Jürgen E Gschwend; Marc C Smaldone; Robert G Uzzo; Alexander Kutikov; Andrea Minervini Journal: J Clin Med Date: 2022-03-23 Impact factor: 4.241